PT848755E - Proteina relacionada com o vegf - Google Patents

Proteina relacionada com o vegf

Info

Publication number
PT848755E
PT848755E PT96931450T PT96931450T PT848755E PT 848755 E PT848755 E PT 848755E PT 96931450 T PT96931450 T PT 96931450T PT 96931450 T PT96931450 T PT 96931450T PT 848755 E PT848755 E PT 848755E
Authority
PT
Portugal
Prior art keywords
vrp
vegf
protein related
postulated
stimulates
Prior art date
Application number
PT96931450T
Other languages
English (en)
Portuguese (pt)
Inventor
William Wood
James Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21706123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT848755(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT848755E publication Critical patent/PT848755E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PT96931450T 1995-09-08 1996-08-30 Proteina relacionada com o vegf PT848755E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US349195P 1995-09-08 1995-09-08

Publications (1)

Publication Number Publication Date
PT848755E true PT848755E (pt) 2003-12-31

Family

ID=21706123

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96931450T PT848755E (pt) 1995-09-08 1996-08-30 Proteina relacionada com o vegf

Country Status (13)

Country Link
US (9) US6451764B1 (enExample)
EP (2) EP1382679A3 (enExample)
JP (3) JPH11514976A (enExample)
AT (1) ATE242809T1 (enExample)
AU (3) AU710696C (enExample)
CA (1) CA2231400A1 (enExample)
DE (1) DE69628652T3 (enExample)
DK (1) DK0848755T4 (enExample)
ES (1) ES2202469T5 (enExample)
IL (2) IL123332A (enExample)
PT (1) PT848755E (enExample)
WO (1) WO1997009427A1 (enExample)
ZA (1) ZA967445B (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
IL123332A (en) * 1995-09-08 2005-12-18 Genentech Inc Isolated biologically active human vascular endothelial growth factor (vegf) related protein
US6994989B1 (en) * 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
AU1116297A (en) * 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
ATE294863T1 (de) 1996-07-15 2005-05-15 Chugai Pharmaceutical Co Ltd Neuartige vegf-ähnliche faktoren
EP1749836B1 (en) * 1996-08-23 2009-06-17 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
US20050163818A1 (en) * 1996-11-05 2005-07-28 Hsing-Wen Sung Drug-eluting device chemically treated with genipin
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR20010034576A (ko) * 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
NZ511408A (en) 1998-10-09 2004-04-30 Licentia Ltd Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000039284A1 (en) * 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
WO2001062942A2 (en) * 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002248372B8 (en) * 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
EP2228389B1 (en) 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Antibodies against vascular endothelial growth factor 2
WO2003006104A2 (en) * 2001-07-12 2003-01-23 Ludwig Institute For Cancer Research Lymphatic endothelial cells materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
WO2003103581A2 (en) * 2002-06-05 2003-12-18 Genentech, Inc. Compositions and methods for liver growth and liver protection
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20050019404A1 (en) * 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
PL1660057T3 (pl) 2003-08-27 2012-10-31 Ophthotech Corp Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US7150970B2 (en) 2004-08-02 2006-12-19 University Of Iowa Research Foundation Methods of inhibiting VEGF-C
EP1799713B1 (en) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7358085B2 (en) 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
AU2010264116B2 (en) * 2009-06-25 2013-12-19 Dupont Nutrition Biosciences Aps Protein
CA2766403A1 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
RU2012114094A (ru) 2009-09-11 2013-10-20 Дженентек, Инк. Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
AR078377A1 (es) 2009-12-11 2011-11-02 Genentech Inc Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
US8472271B2 (en) 2011-02-18 2013-06-25 International Business Machines Corporation Systems and methods for memory device precharging
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
DK2802606T3 (en) 2012-01-10 2018-06-25 Biogen Ma Inc INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
PE20171766A1 (es) 2015-02-04 2017-12-21 Hoffmann La Roche Oligomeros antisentido de tau y usos de estos
WO2016127000A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0321196A3 (en) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
DE394538T1 (de) 1989-04-28 1991-04-11 Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf Hefezellen der schwanniomyces-gattung.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
JPH07504813A (ja) 1992-01-22 1995-06-01 ニユー・イングランド・デイーコネス・ホスピタル 新規蛋白質チロシンキナーゼ類
US5326695A (en) 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
US6228609B1 (en) 1992-07-09 2001-05-08 Systemix, Inc. Soluble Flk-2 sequence
US6107046A (en) 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1995009656A1 (en) * 1993-10-01 1995-04-13 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
AUPM379394A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - i
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
ES2249762T3 (es) * 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
FI964862L (fi) 1994-06-09 1997-02-10 Kari Alitalo FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6818220B1 (en) * 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6245530B1 (en) * 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0815221B1 (en) 1995-03-02 2003-10-22 AMRAD Operations Pty.,Ltd. A novel growth factor and a genetic sequence encoding same
WO1996039421A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
IL123332A (en) 1995-09-08 2005-12-18 Genentech Inc Isolated biologically active human vascular endothelial growth factor (vegf) related protein
ES2341864T3 (es) 1995-09-29 2010-06-29 Universita Degli Studi Di Siena Genes regulados y usos de los mismos.
AU1116297A (en) * 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) * 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
ATE294863T1 (de) * 1996-07-15 2005-05-15 Chugai Pharmaceutical Co Ltd Neuartige vegf-ähnliche faktoren
EP1749836B1 (en) 1996-08-23 2009-06-17 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
WO1998024811A2 (en) 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
KR100244853B1 (ko) * 1996-12-31 2000-02-15 구자홍 가변형 광원과 그를 이용한 이종 광디스크용광픽업 장치
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
IL132537A0 (en) 1997-04-25 2001-03-19 Collateral Therapeutics Truncated vegf-related proteins
DE19748734A1 (de) 1997-11-05 1999-05-06 Biotechnolog Forschung Gmbh Verfahren zur Gewinnung von biologisch aktiven Dimeren von rekombinanten humanen Wachstumsfaktoren aus der Cystein-Knoten-Familie sowie Verwendung der gewonnenen Dimere
KR20010034576A (ko) 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
FR2777904B1 (fr) * 1998-04-24 2000-12-15 Millipore Sa Cassette ainsi que procede et appareil d'analyse de l'air l'utilisant
NZ511408A (en) 1998-10-09 2004-04-30 Licentia Ltd Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU2002248372B8 (en) 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7142876B2 (en) * 2003-03-03 2006-11-28 Nokia Corporation Location dependent services
TW200829215A (en) 2007-01-03 2008-07-16 Univ Nat Chiao Tung Micro probe array and manufacturing method of the trans-print mold thereof

Also Published As

Publication number Publication date
DK0848755T3 (da) 2003-10-06
AU2004218707B2 (en) 2008-05-22
AU2008207460B2 (en) 2011-04-21
DE69628652D1 (de) 2003-07-17
DE69628652T3 (de) 2012-05-03
ES2202469T3 (es) 2004-04-01
AU710696C (en) 2002-10-24
DK0848755T4 (da) 2011-05-23
US20030166873A1 (en) 2003-09-04
ATE242809T1 (de) 2003-06-15
AU2004218707A1 (en) 2004-11-04
JP4763826B2 (ja) 2011-08-31
ES2202469T5 (es) 2011-06-06
AU2008207460A1 (en) 2008-09-11
EP0848755B1 (en) 2003-06-11
JP2010068806A (ja) 2010-04-02
JPH11514976A (ja) 1999-12-21
US20070036813A1 (en) 2007-02-15
IL123332A (en) 2005-12-18
EP0848755B2 (en) 2011-02-09
EP0848755A1 (en) 1998-06-24
DE69628652T2 (de) 2004-04-29
WO1997009427A1 (en) 1997-03-13
US6451764B1 (en) 2002-09-17
EP1382679A3 (en) 2004-11-10
US20080118510A1 (en) 2008-05-22
AU7012896A (en) 1997-03-27
US20040213790A1 (en) 2004-10-28
US20060121025A1 (en) 2006-06-08
US6576608B1 (en) 2003-06-10
US20120230992A1 (en) 2012-09-13
ZA967445B (en) 1998-03-03
CA2231400A1 (en) 1997-03-13
JP2008228730A (ja) 2008-10-02
EP0848755B9 (en) 2004-02-04
US20080213272A1 (en) 2008-09-04
US7629145B2 (en) 2009-12-08
EP1382679A2 (en) 2004-01-21
IL123332A0 (en) 1998-09-24
AU710696B2 (en) 1999-09-30
IL170076A (en) 2011-12-29

Similar Documents

Publication Publication Date Title
PT848755E (pt) Proteina relacionada com o vegf
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
DE69233125D1 (de) Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
PT842273E (pt) Ligando de receptor vegf-c
LU91219I2 (fr) Omalizumab (anticorps humanisé recombinant anti-ige)
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
ATE190667T1 (de) Monoklonale antikörper gegen menschlichen tumornekrosefaktor alpha
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DE69536123D1 (de) Fusionsprotein dass bpTK7 enthält
DE69233724D1 (de) Bindungsdomänen des Serrate-Proteins
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
FI20022285L (fi) Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja
ATE321134T1 (de) Menschlicher fc-gamma-rezeptor iii
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
EP1433792A8 (en) Human receptor proteins, related reagents and methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
DE59209942D1 (de) HCMV-spezifische Peptide und ihre Verwendung
Ainbender et al. Radioautographic studies of poliovirus binding by human immunoglobulins.
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
IT1277827B1 (it) Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
DK0439797T3 (da) Et antistof mod det carboxyl-terminale peptid af rotte-somatotropin-bindende protein
ATE281471T1 (de) Antikörper-testbesteck zur bestimmung von amylin
WO1999019480A3 (en) Human receptor proteins; related reagents and methods